Paolo A Ascierto

Paolo A Ascierto

UNVERIFIED PROFILE

Are you Paolo A Ascierto?   Register this Author

Register author
Paolo A Ascierto

Paolo A Ascierto

Publications by authors named "Paolo A Ascierto"

Are you Paolo A Ascierto?   Register this Author

100Publications

10264Reads

47Profile Views

Preanalytic Variables and Tissue Stewardship for Reliable Next-Generation Sequencing (NGS) Clinical Analysis.

J Mol Diagn 2019 Sep 25;21(5):756-767. Epub 2019 Jun 25.

University of Vermont Health Network, Larner College of Medicine at the University of Vermont, Burlington, Vermont.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jmoldx.2019.05.004DOI Listing
September 2019

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

N Engl J Med 2019 Sep 28. Epub 2019 Sep 28.

From the Royal Marsden NHS Foundation Trust, London (J.L.), and the College of Medicine, Swansea University, Swansea (J.W.) - both in the United Kingdom; the Oncology Institute of Veneto IRCCS, Padua (V.C.-S.), the European Institute of Oncology, IRCCS, Milan (P.F.F.), Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples (P.A.A.), the Immunotherapy and Somatic Cell Therapy Unit, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola (M.G.), and the Center for Immuno-Oncology, Medical Oncology and Immunotherapy, University Hospital, Siena (M.M.) - all in Italy; the University of Colorado Cancer Center, Aurora (R.G.); Aix-Marseille University, Assistance Publique-Hôpitaux de Marseille Hôpital Timone, Marseille (J.-J.G.), and Université de Paris, INSERM Unité 976, Assistance Publique-Hôpitaux de Paris Dermatology and Centres d'Investigation Clinique, Saint Louis Hospital, Paris (C.L.) - both in France; the Maria Sklodowska-Curie Institute-Oncology Center, Warsaw, Poland (P.R.); the University of Michigan, Ann Arbor (C.D.L.); Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas (C.L.C.); the Department of Dermatology, University of Essen, Essen, and the German Cancer Consortium, Heidelberg - both in Germany (D.S.); Universitäts Spital, Zurich, Switzerland (R.D.); Cross Cancer Institute, Edmonton, AB (M.S.), and the Princess Margaret Cancer Centre, Toronto (D.H.) - both in Canada; Tasman Oncology Research, Southport, QLD (A.H.), the Crown Princess Mary Cancer Centre, Melanoma Institute Australia, University of Sydney, Sydney, NSW (M.S.C., G.V.L.), and the Royal North Shore and Mater Hospitals (G.V.L.), Sydney, and the Peter MacCallum Cancer Centre, Melbourne, VIC (G.M.) - all in Australia; General University Hospital Gregorio Marañon and Centro de Investigación Biomédica en Red de Oncología, Madrid (I.M.-R.); the Netherlands Cancer Institute, Amsterdam (J.H.); the Leuven Cancer Institute, Department of General Medical Oncology, University Hospital Leuven, Leuven, Belgium (P.S.); University of California San Diego Health-La Jolla Moores Cancer Center, La Jolla (G.A.D.); the Department of Oncology, Odense University Hospital, Odense, Denmark (L.B.); Bristol-Myers Squibb, Princeton, NJ (J.I.R., A.B., A.M.); Dana-Farber Cancer Institute, Boston (F.S.H.); and the Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (J.D.W.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1910836DOI Listing
September 2019

The great debate at "Immunotherapy Bridge 2018", Naples, November 29th, 2018.

J Immunother Cancer 2019 Aug 15;7(1):221. Epub 2019 Aug 15.

Department of Medicine, Roswell Park Comprehensive Cancer Center, Developmental Therapeutics, Buffalo, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-019-0683-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6696687PMC
August 2019

The Role of BRAF-Targeted Therapy for Advanced Melanoma in the Immunotherapy Era.

Curr Oncol Rep 2019 Jul 29;21(9):76. Epub 2019 Jul 29.

Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Via Mariano Semmola snc, Naples, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-019-0827-xDOI Listing
July 2019

The great debate at "Melanoma Bridge 2018", Naples, December 1st, 2018.

J Transl Med 2019 May 10;17(1):148. Epub 2019 May 10.

Clinical Trials Unit, Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale", Naples, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12967-019-1892-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6509811PMC
May 2019

Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations.

Expert Rev Clin Pharmacol 2019 Mar 24;12(3):259-266. Epub 2019 Jan 24.

a Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics , Istituto Nazionale Tumori IRCCS Fondazione G. Pascale , Napoli , Italy.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17512433.2019.1
Publisher Site
http://dx.doi.org/10.1080/17512433.2019.1570847DOI Listing
March 2019

Frontline Therapy for -Mutated Metastatic Melanoma: How Do You Choose, and Is There One Correct Answer?

Am Soc Clin Oncol Educ Book 2019 Jan 17;39:564-571. Epub 2019 May 17.

4 Massachusetts General Hospital Cancer Center, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_243071DOI Listing
January 2019

CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer.

J Clin Oncol 2018 10 15;36(28):2836-2844. Epub 2018 Aug 15.

Yelena Y. Janjigian, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Johanna Bendell, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Emiliano Calvo, START Madrid, Centro Integral Oncológico Clara Campal, Madrid, Spain; Joseph W. Kim, Yale Cancer Center, New Haven, CT; Paolo A. Ascierto, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples; Filippo de Braud, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy; Padmanee Sharma, The University of Texas MD Anderson Cancer Center, Houston, TX; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Katriina Peltola, Docrates Cancer Center, Helsinki, Finland; Dirk Jaeger, University Hospital Heidelberg, Heidelberg, Germany; Jeffry Evans, University of Glasgow, Glasgow; Ian Chau, Royal Marsden Hospital, London and Surrey, United Kingdom; Christopher T. Harbison, Cecile Dorange, Marina Tschaika, Bristol-Myers Squibb, Princeton, NJ; and Dung T. Le, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.6212DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161834PMC
October 2018

Selecting immuno-oncology-based drug combinations - what should we be considering?

Expert Rev Clin Pharmacol 2018 Oct 8;11(10):971-985. Epub 2018 Sep 8.

a Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics , Istituto Nazionale Tumori IRCCS Fondazione G. Pascale , Napoli , Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17512433.2018.1518713DOI Listing
October 2018

Immunological effects of BRAF+MEK inhibition.

Oncoimmunology 2018 23;7(9):e1468955. Epub 2018 Jul 23.

Department of Dermatology, University Hospital Zürich Skin Cancer Center, Zürich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/2162402X.2018.1468955DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6140547PMC
July 2018

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.

N Engl J Med 2018 May 15;378(19):1789-1801. Epub 2018 Apr 15.

From the Gustave Roussy Cancer Campus Grand Paris and University Paris-Saclay, Villejuif (A.M.M.E., C.R.), Hospices Civils de Lyon Cancer Institute, Cancer Research Center of Lyon, Lyon University, Lyon (S.D.), and Aix-Marseille University, Hôpital de la Timone, Assistance Publique-Hôpitaux de Marseille, Marseille (J.-J.G.) - all in France; Netherlands Cancer Institute-Antoni van Leeuwenhoek (C.U.B., A.C.J.A.) and VU University Medical Center (A.J.M.E.), Amsterdam, and Radboud University Medical Center Nijmegen, Nijmegen (R.K.) - all in the Netherlands; Azienda Ospedaliera Papa Giovanni XXIII, Bergamo (M. Mandala), Istituto Nazionale Tumori Istituto di Ricovero e Cura a Carattere Scientifico Fondazione G. Pascale, Naples (P.A.A.), and Universita Degli Studi Di Siena-Policlinico le Scotte, Siena (M. Maio) - all in Italy; Melanoma Institute Australia, the University of Sydney, and Mater and Royal North Shore Hospitals (G.V.L.) and Westmead and Blacktown Hospitals, Melanoma Institute Australia and the University of Sydney (M.S.C.), Sydney, Princess Alexandra Hospital, University of Queensland, Brisbane (V.A.), Alfred Hospital (A.H.) and Peter MacCallum Cancer Centre (S. Sandhu), Melbourne, VIC, and Fiona Stanley Hospital-University of Western Australia-Edith Cowan University Perth, Perth (A.K.) - all in Australia; Cancer Research Center, Moscow (M.L.); Royal Marsden Hospital, London (J.L.); Hospital Clinic Universitari de Barcelona, Barcelona (S.P.); Maria Sklodowska-Curie Institute-Oncology Center, Warsaw, Poland (P.R.); University Hospital Essen, Essen and German Cancer Consortium, Heidelberg (D.S.), and the Skin Cancer Center, Department of Dermatology, Hannover Medical School, Hannover (R.G.) - all in Germany; Washington University School of Medicine, St. Louis (L.H.-A.); Centre Hospitalier de l'Université de Montréal (CHUM), Centre de Recherche du CHUM, Montreal (R.J.); Christie NHS Foundation Trust, Manchester, United Kingdom (P.L.); Merck, Kenilworth, NJ (N.I.); and the European Organization for the Research and Treatment of Cancer Headquarters, Brussels (S.M., S. Suciu).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1802357DOI Listing
May 2018

International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study.

Authors:
Franck Pagès Bernhard Mlecnik Florence Marliot Gabriela Bindea Fang-Shu Ou Carlo Bifulco Alessandro Lugli Inti Zlobec Tilman T Rau Martin D Berger Iris D Nagtegaal Elisa Vink-Börger Arndt Hartmann Carol Geppert Julie Kolwelter Susanne Merkel Robert Grützmann Marc Van den Eynde Anne Jouret-Mourin Alex Kartheuser Daniel Léonard Christophe Remue Julia Y Wang Prashant Bavi Michael H A Roehrl Pamela S Ohashi Linh T Nguyen SeongJun Han Heather L MacGregor Sara Hafezi-Bakhtiari Bradly G Wouters Giuseppe V Masucci Emilia K Andersson Eva Zavadova Michal Vocka Jan Spacek Lubos Petruzelka Bohuslav Konopasek Pavel Dundr Helena Skalova Kristyna Nemejcova Gerardo Botti Fabiana Tatangelo Paolo Delrio Gennaro Ciliberto Michele Maio Luigi Laghi Fabio Grizzi Tessa Fredriksen Bénédicte Buttard Mihaela Angelova Angela Vasaturo Pauline Maby Sarah E Church Helen K Angell Lucie Lafontaine Daniela Bruni Carine El Sissy Nacilla Haicheur Amos Kirilovsky Anne Berger Christine Lagorce Jeffrey P Meyers Christopher Paustian Zipei Feng Carmen Ballesteros-Merino Jeroen Dijkstra Carlijn van de Water Shannon van Lent-van Vliet Nikki Knijn Ana-Maria Mușină Dragos-Viorel Scripcariu Boryana Popivanova Mingli Xu Tomonobu Fujita Shoichi Hazama Nobuaki Suzuki Hiroaki Nagano Kiyotaka Okuno Toshihiko Torigoe Noriyuki Sato Tomohisa Furuhata Ichiro Takemasa Kyogo Itoh Prabhu S Patel Hemangini H Vora Birva Shah Jayendrakumar B Patel Kruti N Rajvik Shashank J Pandya Shilin N Shukla Yili Wang Guanjun Zhang Yutaka Kawakami Francesco M Marincola Paolo A Ascierto Daniel J Sargent Bernard A Fox Jérôme Galon

Lancet 2018 05 10;391(10135):2128-2139. Epub 2018 May 10.

INSERM, Laboratory of Integrative Cancer Immunology, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France; Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, Sorbonne Universités, Paris, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(18)30789-XDOI Listing
May 2018

Emerging Strategies in Systemic Therapy for the Treatment of Melanoma.

Am Soc Clin Oncol Educ Book 2018 May;38:751-758

From the Istituto Nazionale Tumori "Fondazione G. Pascale," Naples, Italy; Massachusetts General Hospital Cancer Center, Boston, MA; Center for Cancer Research, National Cancer Institute, Bethesda, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_199047DOI Listing
May 2018

The Great Debate at "Melanoma Bridge", Napoli, December 2nd, 2017.

J Transl Med 2018 04 17;16(1):101. Epub 2018 Apr 17.

Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.

View Article

Download full-text PDF

Source
https://translational-medicine.biomedcentral.com/articles/10
Publisher Site
http://dx.doi.org/10.1186/s12967-018-1477-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5905181PMC
April 2018

The influence of diet on anti-cancer immune responsiveness.

J Transl Med 2018 03 20;16(1):75. Epub 2018 Mar 20.

Section of Clinical Nutrition and Nutrigenomics, Department of Biomedicine and Prevention, University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12967-018-1448-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5859494PMC
March 2018

Neoadjuvant therapy in melanoma: the next step?

Lancet Oncol 2018 02 18;19(2):151-153. Epub 2018 Jan 18.

Cancer Institute Gustave Roussy, University Paris-Sud, 98400 Villejuif/Paris-Sud, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30016-0DOI Listing
February 2018

Adjuvant Therapy in Resected Melanoma.

N Engl J Med 2018 02;378(7):680

Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1716071DOI Listing
February 2018

Genetic alterations in main candidate genes during melanoma progression.

Oncotarget 2018 Feb 3;9(9):8531-8541. Epub 2018 Jan 3.

Unit of Cancer Genetics, Institute of Biomolecular Chemistry, National Research Council, Sassari, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.23989DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5823576PMC
February 2018

MEK Inhibitors in the Treatment of Metastatic Melanoma and Solid Tumors.

Am J Clin Dermatol 2017 Dec;18(6):745-754

Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori Fondazione "G. Pascale", Via Mariano Semmola, 80131, Naples, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40257-017-0292-yDOI Listing
December 2017

What is changing in the adjuvant treatment of melanoma?

Oncotarget 2017 Dec 6;8(67):110735-110736. Epub 2017 Dec 6.

Paolo A. Ascierto: Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale", Napoli, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.22988DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762277PMC
December 2017

Anti-PD-1 and PD-L1 antibodies in metastatic melanoma.

Melanoma Manag 2017 Dec 21;4(4):175-178. Epub 2017 Nov 21.

Melanoma, Cancer Immunotherapy & Innovative Therapy Department at National Cancer Institute of Naples, Naples 80131, Italy.

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/mmt-2017-0018
Publisher Site
http://dx.doi.org/10.2217/mmt-2017-0018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6094668PMC
December 2017

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.

N Engl J Med 2017 11 10;377(19):1824-1835. Epub 2017 Sep 10.

From New York University Perlmutter Cancer Center, New York (J.W.); Papa Giovanni XXIII Cancer Center Hospital, Bergamo (M. Mandala), Medical Oncology, National Cancer Institute, Milan (M.D.V.), Oncology Institute of Veneto Istituti di Ricovero e Cura a Carattere Scientifico, Padua (V.C.-S.), Center for Immuno-Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena (M. Maio), Ospedale Policlinico San Martino, Genoa (P.Q.), and Istituto Nazionale Tumori Fondazione Pascale, Naples (P.A.A.) - all in Italy; National and Kapodistrian University of Athens, Athens (H.J.G.); Hospital Clinic de Barcelona, Barcelona (A.M.A.), and General University Hospital Gregorio Marañón, Madrid (I.M.-R.) - both in Spain; Texas Oncology-Baylor Cancer Center, Dallas (C.L.C.); Hospices Civils de Lyon, Pierre Bénite (S.D.), Aix-Marseille University, Hospital de la Timone, Marseille (J.-J.G.), Institut Universitaire du Cancer de Toulouse and Centre Hospitalier Universitaire (CHU), Toulouse (N.M.), Université Lille, INSERM Unité 1189, CHU Lille, Lille (L.M.), and Assistance Publique-Hôpitaux de Paris, Dermatology and Centres d'Investigation Clinique, INSERM Unité 976, Hôpital Saint Louis, Université Paris Diderot, Paris (C.L.) - all in France; Oncology Center Sf. Nectarie, Craiova, Romania (M. Schenker); Princess Margaret Cancer Centre, University of Toronto, Toronto (M.O.B.), and Cross Cancer Institute, Edmonton, AB (M. Smylie) - both in Canada; the Department of Oncology, University of Oxford, Oxford (M.R.M.), and Royal Marsden NHS Foundation Trust, London (J.L.) - both in the United Kingdom; Gallipoli Medical Research Foundation and University of Queensland, Queensland, VIC (V.A.), and Melanoma Institute Australia, University of Sydney, and Royal North Shore and Mater Hospitals, Sydney (G.V.L.) - all in Australia; University of Colorado, Denver (R.G.); Winship Cancer Institute, Emory University School of Medicine, Atlanta (R.R.K.); Georgetown-Lombardi Comprehensive Cancer Center, Washington DC (M.B.A.); University of Washington, Seattle (S.B.); Maria Sklodowska-Curie Institute-Oncology Center, Warsaw, Poland (P.R.); Nagoya University Graduate School of Medicine, Nagoya (K.Y.), and the National Cancer Center Hospital, Tokyo (N.Y.) - both in Japan; Seoul National University Hospital, Seoul, South Korea (T.M.K.); and Bristol-Myers Squibb, Princeton, NJ (V.P, J.S., A.Q.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1709030DOI Listing
November 2017

Immune Checkpoint Inhibitors in Melanoma and HIV Infection.

Open AIDS J 2017 14;11:91-100. Epub 2017 Nov 14.

Oncology Unit, Department of Medicine, Surgery and Dentistry, University of Salerno, via Allende, 84081 Baronissi (Salerno), Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1874613601711010091DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5730951PMC
November 2017

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

N Engl J Med 2017 10 11;377(14):1345-1356. Epub 2017 Sep 11.

From the Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (J.D.W., M.A.P., M.K.C.); Oncology Institute of Veneto Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Padua (V.C.-S.), European Institute of Oncology, Milan (P.F.F.), Center for Immuno-Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena (M.M.), the Immunotherapy and Somatic Cell Therapy Unit, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola (M.G.), and Istituto Nazionale Tumori Fondazione Pascale, Naples (P.A.A.) - all in Italy; University of Colorado, Denver (R.G.); Maria Sklodowska-Curie Institute-Oncology Center, Warsaw, Poland (P.R.); Aix-Marseille University, Hôpital de la Timone, Marseille (J.-J.G.), and Assistance Publique-Hôpitaux de Paris, Dermatology and Centres d'Investigation Clinique, INSERM Unité 976, Hôpital Saint-Louis, Université Paris Diderot, Paris (C.L.) - both in France; Texas Oncology-Baylor Cancer Center, Dallas (C.L.C.); University of Michigan, Ann Arbor (C.D.L.); the College of Medicine, Swansea University, Swansea (J.W.), and Royal Marsden NHS Foundation Trust, London (J.L.) - both in the United Kingdom; the Department of Dermatology, University of Essen, Essen, and the German Cancer Consortium, Heidelberg - both in Germany (D.S.); Cross Cancer Institute, Edmonton, AB (M.S.), and Princess Margaret Cancer Centre, Toronto (D.H.) - both in Canada; Universitäts Spital, Zurich, Switzerland (R.D.); Tasman Oncology Research, Southport Gold Coast, QLD (A.H.), Crown Princess Mary Cancer Centre, Melanoma Institute Australia, University of Sydney (M.S.C.), and Melanoma Institute Australia, University of Sydney, and Royal North Shore and Mater Hospitals (G.V.L.), Sydney, and Peter MacCallum Cancer Centre (G.M.) and the Olivia Newton-John Cancer Research Institute, University of Melbourne (J.C.), Melbourne, VIC - all in Australia; Netherlands Cancer Institute, Amsterdam (J.H.); University Hospitals Leuven, KU Leuven, Leuven, Belgium (O.B.); General University Hospital Gregorio Marañón, Madrid (I.M.-R.); Northwestern University, Chicago (J.S.); Bristol-Myers Squibb, Princeton, NJ (D.W., L.R., R.B.); and the Dana-Farber Cancer Institute, Boston (F.S.H.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1709684DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706778PMC
October 2017

Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge", Napoli, November 30th 2016.

J Transl Med 2017 10 11;15(1):205. Epub 2017 Oct 11.

Department of Urology and Gynecology, Istituto Nazionale Tumori "Fondazione G. Pascale", Naples, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12967-017-1309-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5637331PMC
October 2017

World-Wide Immunoscore Task Force: meeting report from the "Melanoma Bridge", Napoli, November 30th-December 3rd, 2016.

J Transl Med 2017 10 20;15(1):212. Epub 2017 Oct 20.

Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori "Fondazione G. Pascale", Via Mariano Semmola, 80131, Naples, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12967-017-1310-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651599PMC
October 2017

FKBP51s signature in peripheral blood mononuclear cells of melanoma patients as a possible predictive factor for immunotherapy.

Cancer Immunol Immunother 2017 Sep 22;66(9):1143-1151. Epub 2017 Apr 22.

Department of Molecular Medicine and Medical Biotechnologies, Federico II University, Via Pansini, 5, 80131, Naples, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-017-2004-0DOI Listing
September 2017

PD-L1 inhibitors in the pipeline: Promise and progress.

Oncoimmunology 2017 21;7(1):e1365209. Epub 2017 Sep 21.

Melanoma, Cancer Immunotherapy and Innovative Therapies Unit - Istituto Nazionale Tumori Fondazione "G. Pascale," Napoli, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/2162402X.2017.1365209DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739559PMC
September 2017

Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape.

Eur J Cancer 2017 08 15;81:116-129. Epub 2017 Jun 15.

Research Branch, Sidra Medical and Research Centre, Doha, Qatar. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.01.035DOI Listing
August 2017

Checkpoint inhibitors in melanoma and early phase development in solid tumors: what's the future?

J Transl Med 2017 08 8;15(1):173. Epub 2017 Aug 8.

Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12967-017-1278-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5549368PMC
August 2017

Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis.

Eur J Cancer 2017 07 11;79:176-184. Epub 2017 May 11.

Cancer Clinical Trials Unit, Royal Adelaide Hospital, Adelaide, Australia; Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, Australia; Discipline of Medicine, University of Adelaide, Adelaide, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.04.007DOI Listing
July 2017

A multireferral centre retrospective cohort analysis on the experience in treatment of metastatic uveal melanoma and utilization of sequential liver-directed treatment and immunotherapy.

Melanoma Res 2017 06;27(3):243-250

aDepartment of Medical Oncology, Royal North Shore Hospital bDepartment of Medical Oncology Melanoma Institute Australia cDepartment of Medical Oncology, The University of Sydney, Sydney, New South Wales, Australia dDepartment of Medical Oncology, Istituto Nazionale Tumori 'Fondazione Pascale', Naples, Campania, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000343DOI Listing
June 2017

Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care.

BioDrugs 2017 Feb;31(1):51-61

Melanoma, Cancer Immunotherapy and Innovative Therapies Unit, Istituto Nazionale Tumori di Napoli Fondazione "G. Pascale", Via Mariano Semmola, 80131, Naples, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40259-016-0208-zDOI Listing
February 2017

IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patients.

Oncoimmunology 2017 7;6(2):e1261242. Epub 2016 Dec 7.

Tumor Immunology and Immunopathology Laboratory, Department of Experimental and Clinical Medicine, University "Magna Græcia" of Catanzaro, Campus - Germaneto, Catanzaro, Italy; Department of Microbiology, Cell and Tumorbiology (MTC), Karolinska Institutet, Stockholm, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/2162402X.2016.1261242DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5353942PMC
December 2016

Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series.

Br J Cancer 2016 Nov 6;115(11):1280-1284. Epub 2016 Oct 6.

Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione 'G. Pascale', Via Mariano Semmola, 80131 Napoli, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/bjc.2016.321DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129828PMC
November 2016

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.

N Engl J Med 2016 11 7;375(19):1845-1855. Epub 2016 Oct 7.

From Gustave Roussy Cancer Campus Grand Paris, Villejuif (A.M.M.E., C.R.), Aix-Marseille University, Hôpital de La Timone, Marseille (J.-J.G.), Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis, Paris (C.L.), University Lille, INSERM Unité-1189, Centre Hospitalier Universitaire (CHU) Lille, Service de Dermatologie, Lille (L.M.), and CHU Lyon, Lyon (L.T.) - all in France; the Oncology Institute of Veneto-Istituto di Ricovero e Cura a Carattere Scientifico, Padua (V.C.-S.), Istituto Nazionale Tumori Fondazione G. Pascale, Naples (P.A.A.), Istituti Fisioterapici Ospitalieri, Rome (V.F.), University Hospital of Siena, Istituto Toscano Tumori, Siena (M.M.), and the European Institute of Oncology, Milan (A.T.) - all in Italy; University of Zurich Hospital, Zurich, Switzerland (R.D.); Memorial Sloan Kettering Cancer Center, New York (J.D.W.); Aarhus University Hospital, Aarhus (H.S.), and Odense University Hospital, Odense (L.B.) - both in Denmark; the Angeles Clinic and Research Institute, Los Angeles (O.H.); Oncology Specialists, Park Ridge, IL (J.M.R.); Cross Cancer Institute, Edmonton, AB, Canada (M.S.); H. Lee Moffitt Cancer Center, Tampa, FL (J.S.W.); Broomfield Hospital, Chelmsford, United Kingdom (S.T.); Universitätsklinikum Schleswig-Holstein, Kiel (A.H.), and University Hospital Heidelberg, Heidelberg (J.C.H.) - both in Germany; Dana-Farber Cancer Institute, Boston (F.S.H.); Bristol-Myers Squibb, Princeton, NJ (C.T., V.P.); and the European Organization for Research and Treatment of Cancer, Brussels (G.S., S.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1611299DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5648545PMC
November 2016

Complete response to nivolumab monotherapy in a treatment-naive, BRAF wild-type patient with advanced mucosal melanoma and elevated lactate dehydrogenase: a case report from a phase III trial.

Cancer Immunol Immunother 2016 11 7;65(11):1395-1400. Epub 2016 Sep 7.

Istituto Nazionale Tumori Fondazione "G. Pascale", Via Mariano Semmola, 80131, Naples, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-016-1898-2DOI Listing
November 2016

Translational significance of Nodal, Cripto-1 and Notch4 in adult nevi.

Oncol Lett 2016 Aug 21;12(2):1349-1354. Epub 2016 Jun 21.

Cancer Biology and Epigenomics Program, Stanley Manne Children's Research Institute, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL 60611, USA; Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA; Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/ol.2016.4755DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4950573PMC
August 2016